Read our latest news, and find more about us and our portfolio companies.
Change reflects evolution from discovery research to global clinical development company focused on developing innovative immuno-inflammatory regulators.
Inthera Bioscience, a Swiss biopharmaceutical company focused on the development of first-in-class targeted small molecule therapies for solid tumors, today announced the closing
Obseva announced the closing of a CHF 60 (USD 60) million Series B preferred equity financing. The financing included new investors HBM Healthcare Investments, New Enterprise
Dr Brewis joins F-star from GlaxoSmithKline (GSK) where as Vice President, Head of Biopharmaceutical Research he led a global team of 300 scientists who advanced numerous monoclonal
Doctors have long treated autoimmune diseases such as arthritis and lupus as a case of a confused immune system: Immune cells decide healthy tissue looks foreign and wage an attack.
Canbex Therapeutics Ltd today announced that its novel orally active medication for the treatment of spasticity, VSN16R, has entered a Phase II trial in patients with spasticity
Veteran deal-maker and company-builder provides extensive corporate leadership and operational experience as Padlock expands its team and advances multiple programs
Padlock Therapeutics Named by FierceBiotech as a 2015 “Fierce15” Biotech Company
Asceneuron raises CHF 30 million in a Series A financing round led by Sofinnova Partners.
Proceeds will Further Strengthen RaNA’s Proprietary Platform s and Advance Lead Optimization and IND - Enabling Studies for Priority Programs
Creates Industry - Leading R&D Effort Focused on Creating PAD Inhibitors for the Treatment of Autoimmune Diseases ...
Dr. Copeland brings deep experience in oncology drug discovery and development to Raze’s SAB ...
The transaction is expected to close in the second quarter of 2015 ...
Gilead Sciences, Inc. and EpiTherapeutics ApS, a privately-held Danish company, announced the signing of a definitive agreement pursuant ...
Company strengthens its position as a leader in developing new treatments for autoimmune disease focus ed on protein citrullination ...
Progyny, Inc., the new combined entity of Auxogyn, Inc. and Fertility Authority, LLC, announced that it has secured additional capital from investors ...
Lausanne, Switzerland – Asceneuron SA today announced that the Alzheimer’s Drug Discovery Foundation (ADDF) awarded it a USD 325,000 grant ...
Institutions to Conduct Disease - Specific Pre-clinical Studies With the Company’s Proprietary Investigational Compounds ...
SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance ...
Dr. Manfredi joins Raze with nearly two decades of experience in cancer biology ...
Auxogyn, Inc. and Fertility Authority, LLC today announced the merger of the two companies.
The Eeva Test is now commercially available in the United States following its recent FDA clearance.
Lausanne, Switzerland – "The Road To Tau" - Asceneuron, an MS Ventures portfolio company ...
Geneva, Switzerland, 26 February 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromising pregnancy from ...
Geneva, Switzerland, February 24 2015 - Prexton Therapeutics, a biopharmaceutical company developing novel therapeutic compounds for the treatment of CNS conditions including ...
Ipsen (Euronext: IPN; ADR: IPSEY) and Canbex Therapeutics Ltd (Canbex) today announced that Canbex has granted ...
Lausanne, Switzerland - Asceneuron SA, an emerging leader in developing novel small molecule therapeutics targeting tauopathies for Alzheimer’s and ...
Evotec AG and Padlock Therapeutics, Inc. (“Padlock”) announced today that they have successfully completed an initial goal ...
Members Expand Company’s Expertise in Cancer Metabolism Drug Discovery and Development